Very interesting! Or course, this only refers to episodic memory performance, not long-term memory, ability in languages, etc.
One thing I have noticed as an academic -- here speaking in terms of observations on fellow PhDs, not in terms of any studies -- is that there are some people who are extremely good at remembering facts, some people who are extremely good at debating theories, others are very skilled in learning foreign languages, but being high functioning in all areas is *extremely* uncommon.
Prana also has an interest in a MPAC to potentially address ALS -- and here is a story on new ALS research:
Good post. I just saw today that Tanzi was ranked 13th of all scientists in the world in 2013 in a translational science ranking -- right behind David Baltimore (you know, that guy with a Nobel prize. . .). So he's getting up there.
Note that The Nature article itself does not say anything about metals dyshomeostasis, or zinc, or copper, or iron. It really just focuses on this new and much faster way to test Alzheimers in a petri dish without relying on mouse models.
Could you please write only in CAPS and use a few more exclamation points?
Here's my suggestion, go to the CDC, read about Ebola. The CDC, for example, rates it as less contagious than AIDS, far less contagious than mumps . . . Knowledge is power.
Well, let me change my opinion somewhat. The share price is not meaningless, but neither do the share prices of developmental biotechs telegraph information in the same way as a mature company. With a regular company, share price has some relation to sales. PRAN is not evaluated on sales. Prices here ideally reflect progress on scientific benchmarks. I say ideally, because in reality, daily share prices of developmental biotechs also reflect manipulation. As for the idea that I do my DD from message boards: it is interesting that you want to make that charge. Go ahead, think what you want about all the "crazy" people posting abstracts, and their mindless posts, and instead fixate on share price. Go ahead.
You're ready to hit the sell button because of a few Ebola cases in the US where people were brought to hospitals? This is no time to sing halleluia -- Ebola IS a worry -- but you're going overboard.
Wrong. Some of us -- gasp!!!! -- confirm our initial DD by reading the abstracts and sometimes the studies. For this company, the share price is meaningless, the scientific progress everything.
Another that I wonder about is Wilson's disease, which leads to excess copper in the liver but also in the brain. Thoughts?
Manipulated, yes. And that manipulation was abetted, in part but not in whole, by weak hands. Personally, I would like to see it made illegal to borrow shares for such shenanigans. But if you are REALLY a long, then you expect, in a year, that this stock will be much higher anyhow based on sales.
I hardly believe that all shorts are bad. Some are good. They help the market at times. But some hedge funds manipulate stocks, and biotech is a prime arena for this. KERX dropped substantially on good news that some shorts completely misrepresented. The amount of utter nonsense we see on these boards -- the pandering to emotion, the sheer misrepresentation of results, and so on -- mean that longs have good reasons not to trust some shorts.